FDA Approval Targets Rare Kidney Disease - Scorecard - MDSpire
Advertisement
FDA Approval Targets Rare Kidney Disease
Phase 3 data showed greater proteinuria reduction vs irbesartan, with similar tolerability and a 1.1 mL/min/1.73 m² difference in estimated glomerular filtration rate at 108 weeks.
Clinical Scorecard: FDA Approval Targets Rare Kidney Disease
At a Glance
Category
Detail
Condition
Focal segmental glomerulosclerosis without nephrotic syndrome
Key Mechanisms
Sparsentan targets endothelin A and angiotensin II receptors to reduce inflammation and scarring in the kidney
Target Population
Adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis without nephrotic syndrome
Care Setting
Specialist nephrology care with monitoring capabilities
Key Highlights
First FDA-approved pharmacologic treatment for focal segmental glomerulosclerosis without nephrotic syndrome
Phase 3 DUPLEX trial showed 46% proteinuria reduction with sparsentan vs 30% with irbesartan at 108 weeks
Sparsentan has a similar tolerability profile to irbesartan but requires liver function monitoring due to hepatotoxicity risk
Guideline-Based Recommendations
Diagnosis
Confirm focal segmental glomerulosclerosis diagnosis by biopsy or genetic testing
Assess proteinuria levels to determine eligibility
Management
Initiate sparsentan to reduce proteinuria in patients aged 8 years and older without nephrotic syndrome
Avoid sparsentan in pregnancy due to embryo-fetal toxicity
Use restricted risk evaluation and mitigation strategy program for dispensing
Monitoring & Follow-up
Assess liver function before treatment initiation and regularly during therapy
Monitor blood pressure, potassium levels, and signs of peripheral edema
Observe for adverse effects such as hypotension, dizziness, and anemia
Risks
Hepatotoxicity requiring liver function monitoring
Contraindicated in pregnancy due to embryo-fetal toxicity
Potential adverse effects include hypotension, hyperkalemia, peripheral edema, dizziness, and anemia
Patient & Prescribing Data
Approximately 30,000 US patients with focal segmental glomerulosclerosis without nephrotic syndrome; broader population exceeds 100,000 including other indications
Sparsentan demonstrated superior proteinuria reduction compared to irbesartan with comparable tolerability in both adult and pediatric patients
Clinical Best Practices
Confirm diagnosis with biopsy or genetic testing prior to treatment
Perform baseline and ongoing liver function tests due to hepatotoxicity risk
Educate patients on potential side effects and contraindications, especially pregnancy risks
Use sparsentan within a restricted REMS program to ensure safe use
Monitor renal function and proteinuria regularly to assess treatment efficacy
